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Abstract
Background
Diabetic cardiomyopathy (DM CMP) is defined as cardiomyocyte damage and ventricular
dysfunction directly associated with diabetes independent of concomitant coronary artery
disease or hypertension. Matrix metalloproteinases (MMPs), especially MMP-2, have been
reported to underlie the pathogenesis of DM CMP by increasing extracellular collagen
content.
Purpose
We hypothesized that two discrete MMP-2 isoforms (full length MMP-2, FL-MMP-2; N-termi-
nal truncated MMP-2, NTT-MMP-2) are induced by high glucose stimulation in vitro and in
an experimental diabetic heart model.
Methods
Rat cardiomyoblasts (H9C2 cells) were examined to determine whether high glucose can
induce the expression of the two isoforms of MMP-2. For the in vivo study, we used the
streptozotocin-induced DM mouse heart model and age-matched controls. The changes of
each MMP-2 isoform expression in the diabetic mice hearts were determined using quantita-
tive real-time polymerase chain reaction (qRT-PCR). Immunohistochemical stains were
conducted to identify the location and patterns of MMP-2 isoform expression. Echocardiog-
raphy was performed to compare and analyze the changes in cardiac function induced by
diabetes.
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Results
Quantitative RT-PCR and immunofluorescence staining showed that the two MMP-2 iso-
forms were strongly induced by high glucose stimulation in H9C2 cells. Although no definite
histologic features of diabetic cardiomyopathy were observed in diabetic mice hearts, left
ventricular systolic dysfunction was determined by echocardiography. Quantitative RT-PCR
and IHC staining showed this abnormal cardiac function was accompanied with the
increases in the mRNA levels of the two isoforms of MMP-2 and related to intracellular
localization.
Conclusion
Two isoforms of MMP-2 were induced by high glucose stimulation in vitro and in a Type 1
DM mouse heart model. Further study is required to examine the role of these isoforms in
DM CMP.
Introduction
Diabetic cardiomyopathy (DM-CMP) is defined as diabetes mellitus (DM)-induced ventricu-
lar dysfunction independent of concomitant coronary artery disease or hypertension [1,2].
The Framingham study demonstrated that heart failure in 6% of men and 12% of women can
be attributed solely to DM [3]. The pathophysiology of this heart failure is complex and has
been associated with enhanced reactive oxygen species (ROS) production, advanced glycation
end product (AGE) formation, and protein kinase C signaling provoked by hyperglycemia,
hyperinsulinemia, and hyperlipidemia [4]. Recent data indicate that defects in mitochondrial
biogenesis also underlie the pathophysiology of diabetic cardiomyopathy [5–7]. Despite these
recent advances in our understanding of the pathophysiology of diabetic cardiomyopathy, spe-
cific therapeutic options remain limited.
Previous reports have indicated that specific matrix metalloproteinases (MMPs) play
important roles in several forms of cardiac disease, including ischemia-reperfusion (I/R)
injury, post-infarction left ventricular remodeling, heart failure, and dilated cardiomyopathy
[8–11]. Matrix metalloproteinase-2 (MMP-2) has been extensively studied in both experimen-
tal models and human cardiac disease and has been a therapeutic target in a limited number of
clinical trials [12–14]. Until recently, both experimental and human studies were focused on
the pathophysiologic roles of the full length MMP-2 isoform (FL-MMP-2), which has both
extra- and intracellular proteolytic targets. The latter include sarcomeric troponin I, myosin
light chain 1 and titin, with resultant diminishment of contractile function [15–17]. We
recently reported on a novel intracellular, N-terminal truncated isoform of MMP-2
(NTT-MMP-2) generated by oxidative stress-mediated activation of an alternate promoter
located in the first intron of the MMP-2 gene [18]. The NTT-MMP-2 isoform is localized to
the mitochondrial intramembranous space and initiates cellular regulated necrosis by induc-
tion of the mitochondrial permeability transition [19].
We previously determined that the NTT-MMP-2 isoform is expressed in cardiomyocytes
from mice with accelerated atherogenesis and myocardial infarction, as well as in the setting of
aging [20]. Cardiac-specific transgenic expression of the NTT-MMP-2 isoform results in sys-
tolic failure associated with cardiomyocyte necrosis and inflammation [21]. In the present
study we evaluated the expression of the MMP-2 isoforms in an experimental model of Type I
Isoforms of matrix metalloproteinase-2 in diabetic heart
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diabetes mellitus and demonstrate an association between NTT-MMP-2 isoform expression,
mitochondrial injury and systolic dysfunction.
Materials and methods
H9C2 cell culture experiments
Rat cardiomyoblasts (H9C2 cells) were purchased from American Type Culture Collections
(ATCC, Rockville, MD, USA) and maintained in Dulbecco’s Modified Eagle’s Media
(DMEM) (Gibco, Paisley, UK) containing 1.0g/L D-glucose supplemented with 10% fetal
bovine serum (FBS) (Gibco). Cells were incubated at 37˚C in a humidified incubator contain-
ing 5% CO2 and then cultured in the presence of 30mM D-glucose for 2 or 24 hrs and com-
pared with controls maintained in normal glucose containing medium.
Immunofluorescence of H9C2 cells
H9C2 cells were grown on sterilized glass coverslips in 6-well plates, washed with phosphate-
buffered saline (PBS), fixed with 4% buffered paraformaldehyde for 20 minutes at 4˚C and per-
meabilized in 0.1% Triton X-100/PBS for 10 minutes at 4˚C. They were then incubated with
FL anti-MMP2 antibody (ab3158, Abcam, Cambridge, UK) diluted 1:20 with 0.05% bovine
serum albumin (BSA)/PBS or an affinity-purified NTT-MMP-2 specific antibody targeting the
S1’ substrate binding loop at 5 μg/ml in 0.05% BSA/PBS [18,22]. Both primary antibody incu-
bations were performed at 4˚C overnight.
Coverslips were then incubated with fluorescein isothiocyanate (FITC)-conjugated second-
ary antibody (Molecular Probes) for FL-MMP-2 (1:1,000, Alexa fluor1 488 rabbit anti-mouse
IgG), and NTT-MMP-2 (1:800, Alexa fluor1 488 rabbit anti-goat IgG) at room temperature
for 30 minutes. Cell nuclei were stained with DAPI (4,6-diamidino-2-phenylindole) (Molecu-
lar Probes, Oregon, USA) at 1:20,000 for 10 minutes and with 20 nM of Mitotracker Red
(M7512, Invitrogen, Korea) for 25 minutes to visualize mitochondria. After mounting cover-
slips on microscopy glass slides with fluorescent mounting medium (Dako, Carpinteria, CA,
USA), images were obtained with a Leica TCS-SP8 confocal microscope (Leica, Mannheim,
Germany). Immunofluorescence intensities as well as Mitotracker staining which were nor-
malized per each cell number (DAPI signal) were measured with the Image J program (NIH,
USA) and were presented with mean ± standard deviation. Every experiment was repeated at
least 3 times.
Quantitative real-time reverse transcriptase-polymerase chain reaction
(RT-PCR)
MMP-2 mRNA isoform levels were assessed by quantitative RT-PCR. For the cardiac tissue,
weight of each sample was ranged from 0.08g to 0.1g. Total RNA was extracted using 1ml of
TRIzol reagent (Thermo Fisher Scientific Inc, CA, USA) for each sample according to the
manufacturer’s instructions. After centrifuge, we collected 400μl of supernatant to 1.5ml tube,
and then RNA was extracted. Acquired total RNA was quantified with SynergyTM H1 hybrid
reader (BioTek Instruments Inc, Winnosk, VT, USA). All tissues were normalized after
repeated total RNA measurement, and total RNA (5 μg) was used to synthesize cDNA using
oligo-dT primers and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV
RTase, Promega, Madison WI, USA). The reaction was performed at 42˚for 1 hour. The prim-
ers used for RT-PCR are described in Table 1. Amplification was conducted over 40 cycles
(95˚C for 15 seconds; 60˚C for 45 seconds; and 72˚C for 1 minute) using Fast Start Universal
SYBR Green Master Mix (Rox dye, Roche) and an ABI 7500 Real-time PCR system (Applied
Isoforms of matrix metalloproteinase-2 in diabetic heart
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Biosystems). β-actin was used as internal control and all products were verified by melting
curve analysis (95˚C 15 sec, 60˚C 15sec, 95˚C 15sec). Gene normalization was performed by
comparing with the expression of the other internal control gene between different samples,
and fold-changes were determined using the 2-ΔΔCT method. Experiments were repeated at
least 3 times to see similarity of the results.
Murine diabetic cardiomyopathy model
Ethical aspects of the study protocol (PNUH 2016–098) were reviewed and approved by the
Pusan National University-Institutional Animal Care and Use Committee (PNU-IACUC).
Eight-week-old C57/BL6j male mice were obtained from Koatech Technology Corporation
(Korea) and randomly allocated to a diabetic or a control group (8 mice/group). Type I diabe-
tes mellitus was induced by injecting streptozotocin intraperitoneally (40 mg/kg in citrate
buffer, pH 4.5, Sigma-Aldrich) for 5 consecutive days. Blood glucose levels were measured by
tail puncture using a blood glucometer 1 week after the final injection. Body weights were mea-
sured weekly and blood glucose concentrations were monitored in the first 2 weeks and every
four weeks thereafter to confirm sustained hyperglycemia. Hyperglycemia was defined as a
blood glucose level>300 mg/dL. Hearts were harvested under isoflurane anesthesia after per-
fusion with 4˚C PBS at 12 weeks post-injection. Those mice were sacrificed by rapid cardiect-
omy after given ketamine/xylazine (80mg/kg IP for ketamine, 10mg/kg IP for xylazine), and
tissue harvest as described below. Cardiac apices from 8 animals were retained for quantitative
RT-PCR and electron microscopic examination (4 animals for gelatin zymography study).
Remaining portions were fixed in 10% neutralized formalin for the immunohistochemistry
(IHC) study.
Gelatin zymography
Zymography was performed to determine MMP-2 activities in heart tissues. Cardiac protein
was extracted using lysis buffer (25mM Tris-HCl, pH 7.5, 100mM NaCl, 1% NP-40) 120μg per
30mg of heart tissue, and then centrifuged at 16000g for 10 min at 4˚C. Saved supernatant was
measured with Bradford protein assay. A total of 50μg of protein was equally loaded in each
sample. Gelatinase activity was determined by electrophoresis on 8% SDS-PAGE gels contain-
ing 0.1% (w/v) gelatin. Gels were incubated for 40 min in zymogram renaturing buffer (Koma-
biotech, Korea) at room temperature, washed in distilled water, and then incubated for 36
hours in zymogram developing buffer (Komabiotech, Korea) at 37˚C according to the manu-
facturer’s instructions. MMP gelatinolytic activities were detected after staining the gels with
Coomassie Brilliant Blue R250 as clear bands on a blue background.
Immunohistochemistry analysis
Formalin-fixed, paraffin-embedded tissue blocks were sectioned at 3μm, deparaffinized in
xylene, hydrated in a graded ethanol series, rinsed with distilled water, and washed with PBS.
Table 1. Primer sequences used for quantitative real-time polymerase chain reactions.
Genes Forward (5’!3’) Reverse (5’!3’)
Full length MMP-2 (rat) TCGCCCATCATCAAGTTCCC GGGCAGCCATAGAAGGTGTT
N-terminal truncated MMP-2 (rat) GCTGTATGTCCTGTCGCT CAA CT GGGCAGCCATAG AAGGTGTT
Full length MMP-2 (mouse) GACCTCTGCGGGTTCTCTGC TTGCAACTCTCCTTGGGGCAGC
N-terminal truncated MMP-2 (mouse) GTGAATCACCCCACTGGTGGGTG TTGCAACTCTCCTTGGGGCAGC
β-actin (mouse control) CTCTCTTCCAGCCTTCCTTCC CTCCTTCTGCATCCTGTCAGC
https://doi.org/10.1371/journal.pone.0221798.t001
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Sections were stained with Hematoxylin-Eosin stain (H&E), Masson’s Trichrome (MT), and
Periodic acid-Schiff (PAS) stain. IHC was performed using the avidin-biotin complex tech-
nique using VIP (Vector labs, USA) as chromogen. Sections were then incubated for 30 min in
methanol containing 3% H2O2 (to block endogenous peroxidase activity), washed with PBS,
and incubated overnight at 4˚C with primary antibody for pre-diluted FL anti-MMP-2 anti-
body (FL-MMP2, ab3158, Abcam, UK) or NTT-MMP-2 (affinity purified, 5 ug/ml). Immuno-
labeling was detected using biotinylated immunoglobulins followed by Vector stain ABC
complex (Vector). All slides were counterstained with methyl green. Quantitative IHC analysis
was performed using the Aperio Positive Fixel Count Algorithm with an Aperio Scan Scope
analyzer (Leica, Germany), and the Image J program (NIH, USA). Randomly selected 5 sec-
tions in high resolution (x400 magnification) of 3 slides from control group and from 8 slides
of diabetic group were analyzed. They were presented as % signal area (normalized to the tis-
sue mass of each sections) and analyzed.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining
To quantify nuclear DNA damage levels, cells were stained using the immunofluorescent
TUNEL technique (kit S7110; Millipore, Darmstadt, Germany). Slides were mounted using
70% glycerol in PBS mounting solution. Cells exhibiting positive nuclear staining, indicative of
DNA fragmentation, were visualized directly under a 40X confocal microscope (Leica, Ger-
many). The number of TUNEL-positive cells were counted in at least 3 random fields per
section.
Electron microscopic analysis
LV apex tissues or H9C2 cells were pre-fixed with 2.5% glutaraldehyde (4˚C, phosphate buffer,
pH 7.2), and then post-fixed with 1% osmium tetroxide in the same buffer. Samples were then
dehydrated using an ethanol series and embedded in epoxy resin (Epon 812). Thick sections
(1μm) were stained with 1% toluidine blue for light microscopy, and thin sections (50~60nm)
were prepared using an ultramicrotome (EM UC7, Leica), and double stained with uranyl ace-
tate and lead citrate. Thin sections were examined by transmission electron microscopy (JEM-
1200EXII, JEOL). Subcellular structures of organelles were reviewed and degrees of mitochon-
drial abnormality were assessed semi-quantitatively using the scoring system described in
Table 2.
Transthoracic echocardiography
Cardiac function was assessed by transthoracic echocardiography under anesthesia. Three
mice from the control group and six mice from the diabetic group were selected for echocardi-
ography. Chest hair was removed with a hair removal gel before image acquisition and a
Table 2. The electron microscopy based scoring system used to assess mitochondria damage.
Damage
score
Description
Mild Number of mitochondria with ruptured membrane�25% at randomly selected 5 samples from 10K
magnification
Moderate Number of mitochondria with ruptured membrane >25% and�75% at any samples from randomly
selected 5 samples from 10K magnification
Severe Number of mitochondria with ruptured membrane�75% at any sample from randomly selected 5
samples from 10K magnification
https://doi.org/10.1371/journal.pone.0221798.t002
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warming pad was used to reduce heat loss. For each mouse, parasternal long-axis and short-
axis views and M-mode images were obtained at the left ventricular (LV) papillary muscle
level. We used a GE Vivid7 and a 10 MHz linear probe for the cardiac examinations, and
images were acquired using a frame rate of 400 f/s, a minimal depth of 1.5 cm, and sweep
speed of 100 mm/s. For echocardiographic measurements of LV systolic function, LV inter-
ventricular septal thickness (IVS), LV internal dimensions (LVID), and posterior wall thick-
nesses (PW) at diastole and systole (IVSd, LVIDd, PWd, and IVSs, LVIDs, PWs, respectively)
were measured using M-mode images. LV ejection fraction (EF) and LV fractional shortening
(FS) were calculated using the following formulae.
EF ð%Þ ¼ 100 x ½ðLVIDd3  LVIDs3Þ=LVIDd3�
FS ð%Þ ¼ 100 x ½ðLVIDd  LVIDsÞ=LVIDd�
Statistical analysis
The analyses were performed using GraphPad Prism 5.0 (GraphPad Software). Results are pre-
sented as mean ± standard deviation. The Mann-Whitney U test or the Kruskal-Wallis test
were used for intergroup comparisons, as appropriate. Statistical significance was accepted for
p values< 0.05.
Results
High glucose stimulation induces both MMP-2 isoforms in H9C2
cardiomyoblasts
Immunofluorescence staining of H9C2 cells showed FL-MMP-2 and NTT-MMP-2 levels
were elevated by high glucose stimulation for 24 hrs as compared to the non-treated control
group (FL-MMP-2: 5.65 ± 0.17% in treated group vs. 3.12 ± 1.03% in control group, p =
0.029, NTT-MMP-2: 6.75 ± 1.18% in treated group vs. 3.26 ± 0.52% in control group, p =
0.042). FL-MMP-2 staining was observed diffusely throughout the cytosol. In contrast,
NTT-MMP-2 immunofluorescence staining analysis showed a more punctate expression pat-
tern consistent with a previously reported mitochondrial localization [19]. (Fig 1, panel A, a-
d). Furthermore, high glucose stimulation induced FL-MMP-2 mRNA expression time-
dependently in H9C2 cells as determined by quantitative RT-PCR (1.00 ± 0.07 fold at 2 hr;
2.4 ± 0.07 fold, p = 0.001 at 24 hr vs. non-treated controls). NTT-MMP-2 mRNA expression
was also significantly increased by high glucose stimulation (1.19 ± 0.09 fold at 2 hr;
2.05 ± 0.17 fold, p = 0.014, at 24 hr vs. non-treated controls) (Fig 1, panel B). Mitotracker
staining showed that high glucose stimulation numerically reduced overall mitochondria
numbers which was associated with fragmentation in H9C2 cells. However, there was no sta-
tistical difference between two groups (9.78 ± 2.15% in control group vs. 7.9 ± 1.59% in
treated group, p = 0.571) (Fig 1 panel C).
Transmission electron microscopy of H9C2 cells confirmed and extended the results seen
at the light microscopy level with Mitotracker. As shown in Fig 2, culture of H9C2 cells in high
glucose medium for 24 hours resulted in mitochondrial swelling, loss of organized cristae
structure and fragmentation consistent with the mitochondrial permeability transition. In
addition, there was evidence for mitochondrial autophagy (mitophagy). Thus, culture of cardi-
omyoblast H9C2 cells in high glucose medium induces MMP-2 isoform expression associated
with light and transmission electron microscopy findings characteristic of the mitochondrial
permeability transition.
Isoforms of matrix metalloproteinase-2 in diabetic heart
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Diabetic mice exhibit decreased LV systolic function in the absence of
structural changes
Echocardiography was performed to evaluate cardiac functional changes 12 weeks following
induction of Type 1 diabetes mellitus and compared to age-matched litter mate controls.
Mean body and heart weights were similar between the two groups (diabetic group
27.17 ± 1.72 g and 0.19 ± 0.02 g, vs. control 26.0 ± 3.37g and 0.18 ± 0.02g, p = 0.557 and
p = 0.191, respectively). Mean heart to body weight ratios were comparable in both groups
(0.70 ± 0.04% vs. 0.68 ± 0.05%, p = 0.409). Hematoxylin and eosin (H&E) staining showed no
definite inflammatory cell infiltration, cardiomyocyte sarcomeric disorganization or necrosis
in the diabetic group (Fig 3, panel A, a,b). Masson’s trichrome (MT) staining showed no evi-
dent increase in fibrosis in the diabetic group as compared to controls (Fig 3, panel A, c, d).
Periodic acid-Schiff (PAS) staining showed no definite increase in advanced glycation end
Fig 1. Expressions of the two MMP2 isoforms in 30mM glucose stimulated H9C2 cells. (A) Immunofluorescence staining of H9C2 cells stimulated for different
times. a: FL-MMP-2 staining after exposure to normal glucose for 24hours (x400) showing minimal staining in cytosol, b: NTT-MMP-2 staining after exposure to
normal glucose for 24 hours (x400) was negative, c: FL-MMP-2 staining after exposure to 30 mM glucose 24 hours (x400) showing FL-MMP-2 was highly expressed
throughout cytosol, d: NTT-MMP-2 staining after exposure to FL-MMP-2 30mM glucose for 24hours (x400) was localized to punctate lesions throughout cytosol and
near nuclei. e: Immunofluorescence density analysis of FL- and NTT-MMP-2 in H9C2 cells using the Image-J program showing increased FL- and NTT-MMP-2
staining after 30mM glucose stimulation as compared with normal glucose stimulation. Each IF signal was normalized to cell number of DAPI signal. (B) Real-time
quantitative PCR of the two isoforms of MMP-2 after normal or 30mM glucose stimulation. mRNA levels of FL- and NTT-MMP-2 isoforms were significantly increased
at 24hours of 30mM glucose exposure, as compared with after exposure for 0 (baseline) or 2 hours. (C) Mitotracker results for H9C2 cells treated with different glucose
concentrations. a, c: low (x400) and high (x800) magnification photographs of H9C2 cells exposed to normal glucose showing normal rod shapes and mitochondria
evenly distributed in cytosol. b, d: low (x400) and high (x800) magnification photographs of H9C2 cells exposed to 30mM glucose exposure showing centrally located
fragmented, short mitochondria, around nuclei (white arrows). e: Mitotracker density analysis showed a trend of decreased density in high glucose group compared to
control group. Each IF signal was normalized to cell number of DAPI signal.
https://doi.org/10.1371/journal.pone.0221798.g001
Isoforms of matrix metalloproteinase-2 in diabetic heart
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Fig 2. Electron microscopic evaluation of H9C2 cells showing mitochondria were damaged by exposure to 30mM glucose. (A) H9C2 cells exposed to normal
glucose for 24 hours. a: H9C2 cells exposed to normal glucose for 24 hours (x12,000), b: Close up of a (yellow box) shows normally sized, well organized mitochondria
(thick red arrows) and intracellular organelles. Materials and myofilaments in cytosol were evenly distributed (thin blue arrows) (x30,000). (B) H9C2 cells exposed to
30mM glucose for 24 hours. a: Many small, abnormal mitochondria were distributed throughout cytosol. b: Abnormal small, mitochondria lacking cristae. Abnormal
vacuoles (thin red arrows) and sparse cytosolic materials including myofilaments (thin blue arrows).
https://doi.org/10.1371/journal.pone.0221798.g002
Isoforms of matrix metalloproteinase-2 in diabetic heart
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product deposition or coronary artery hyalinization in the diabetic hearts as compared to con-
trols. (Fig 3, panel A, e, f). Only rare TUNEL-positive cardiomyocytes were observed in the
diabetic hearts and this was not significantly increased as compared to controls. (Fig 3, panel
A, g, h).
Although we did not observe any histological changes characteristic of diabetic cardiomy-
opathy in the diabetic group at 12 weeks, functional changes were evident as compared to the
control group. Diabetic hearts had significantly larger LV systolic dimensions and lower LVEF
and FS than control hearts (LV internal dimension at systole; 1.88 ± 0.33mm vs. 3.03 ±
0.95mm, p = 0.03, LVEF; 71.25 ± 4.35% vs. 50.67 ± 13.5%, p = 0.012, and FS; 35 ± 3.56% vs.
22.17 ± 7.88%, p = 0.009, respectively) (Fig 3, panel B, C). No significant intergroup differences
were observed between LV mass, LV internal dimensions at diastole, or interventricular septal
Fig 3. Histologic and functional changes in diabetic mouse hearts. (A) Optical microscopic findings. a,b: H&E stained control and DM mouse sections. c, d: MT
stained control and DM mouse sections. e, f: PAS stained control and DM mouse sections. g, h: TUNEL stained control and DM mouse sections. No evidence of tissue
injury, such as inflammation, sarcomere disruption, apoptosis, necrosis, or fibrosis (x200), was observed. (B) Transthoracic echocardiogram of control (left panel) and
the STZ-induced diabetic mice hearts (right panel). LV internal dimensions at diastole; LVIDd, LV internal dimension at systole; LVIDs, LV ejection fraction; LVEF,
fractional shortening; FS. (C) Analysis of echocardiogram measurements. a: LVIDd (mm), b; LVIDs (mm), c; LVEF (%), d: FS (%), e: LV mass (g), f: heart/total body
weight ratio. [abbreviations: LVIDd, left ventricular internal dimension at diastole; LVIDs, left ventricular internal dimension at systole; LVEF, left ventricular ejection
fraction; FS, fractional shortening].
https://doi.org/10.1371/journal.pone.0221798.g003
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thickness, which represent LV structural remodeling. However, there was increased collagen
accumulation analyzed by MT staining at 24 weeks (S1 Fig).
MMP-2 isoform expression is increased in diabetic hearts with distinctive
patterns
As shown in Fig 4, panel A, a, there is a low, but detectable amount of FL-MMP-2 IHC staining
of control cardiac cross sections in both the right and left ventricles. In contrast the
NTT-MMP-2 isoform was not detectable by IHC in the control ventricles (Fig 4, panel A, b).
At 12 weeks following induction of Type I diabetes mellitus there are significant increases in
the IHC staining for both isoforms (Fig 4, panel a, c, d). Interestingly, staining for both iso-
forms was most prominent within the myocardium, with relative little expression on the
epicardial and endocardial surfaces.
Quantitative pixel counting of MMP-2 isoform IHC staining showed significantly greater
positive staining rates for both MMP-2 isoforms in the ventricles of diabetic mice: FL-MMP-2:
56.6 ± 5.0% vs. 25.5 ± 4.5%; NTT-MMP-2; 65.4± 2.9% vs. 27.2 ± 4.2%; for controls and diabetic
mice, respectively, p<0.001. Fold expression levels of the MMP-2 isoforms are shown in Fig 4,
Panel B.
The results of higher powered microscopy analysis of IHC staining of control and diabetic
hearts for the FL-MMP-2 and NTT-MMP-2 isoforms are summarized in Fig 5. There is low,
but detectable expression of the FL-MMP-2 isoform in ventricles of control mice, while the
NTT-MMP-2 isoform was not detectable in controls (Fig 5, Panel A, a, b). At 12 weeks follow-
ing induction of diabetes mellitus, there were significant increases in IHC staining for both iso-
forms (Fig 5, Panel A, c, d). Quantitative analysis revealed that 7- and 26-folds increased
expression of FL-MMP-2 and NTT-MMP-2, respectively (FL-MMP-2; 0.07±0.06% vs. 0.52
±0.24%, p<0.0001, NTT-MMP-2; 0.14±0.15% vs. 3.73±3.62%, p = 0.0026). IHC staining of the
FL-MMP-2 isoform revealed decoration of sarcomeres, while the NTT-MMP-2 isoform stain-
ing was particulate in nature, consistent with our previously reported mitochondrial localiza-
tion [19]. Real-time quantitative PCR analysis showed increased expression of both isoforms
of MMP-2 at 12 week of diabetic induction (FL-MMP-2: 1.56 ± 0.66 fold in diabetic group vs.
control group, p = 0.02, NTT-MMP-2: 2.14 ± 1.18 fold in diabetic group vs. control group,
p = 0.09) (Fig 5, Panel B). Higher power light microscopic examination of the distribution of
cardiomyocyte NTT-MMP-2 staining revealed a complex intracellular distribution. There was
evidence of IHC staining for this isoform on the Z-lines of individual cardiomyocytes, as well
as in the subsarcolemmal area and the intercalated discs (Fig 5, Panel C, D).
Quantitative gelatin zymography of ventricular extracts confirmed increased expression of
MMP-2 at 12 week following induction of diabetes mellitus. As shown in Fig 6, there is an
approximate 1.5-fold increase in total gelatinase activity in ventricular extracts of diabetic mice
as compared to age-matched litter mate controls. As the resolution of gelatin zymography is
insufficient to distinguish between the 68 kDa FL-MMP-2 and the 65 kDa NTT-MMP-2 iso-
forms, the data are given as total gelatinase activity.
The degree of NTT-MMP-2 expression and mitochondrial structural
damage
Electron microscopy was used to score in a semi-quantitative manner the degree of mitochon-
drial structural abnormalities as in Table 2 and compared to qPCR quantitation of MMP-2 iso-
form transcript abundance. The results of these studies are summarized in Fig 7. As compared
to controls, mitochondria from hearts at 12 weeks following induction of diabetes mellitus dis-
played to typical morphologic changes of the mitochondrial permeability transition, with
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swelling, loss of mitochondrial membrane integrity, dissolution of cristae and mitochondrial
rupture and fragmentation. The more severe the degree of mitochondrial damage was, the
Fig 4. Immunohistochemical stain for two isoforms of MMP-2. (A) IHC expression of the two MMP-2 isoforms in transverse sectional images (papillary
muscle level) of control and STZ-induced diabetic mouse hearts. MMP-2 expressing areas were colored using yellow or red dots using a staining intensity
algorithm. a: FL-MMP-2 staining was minimal at 12 weeks after streptozotocin injection control mice. b: NTT-MMP-2 was not expressed in non-diabetic
control mice. c: FL-MMP2 was expressed strongly in the near whole area of the section in diabetic mouse hearts. d: NTT-MMP-2 was also strongly expressed
and its expression pattern was similar to that of FL-MMP-2 in diabetic mouse hearts. (B) Stained pixel numbers were counted using the Aperio Positive Pixel
Count Algorithm. IHC pixel density analysis of FL- and NTT-MMP-2 in transverse section images showed greater expressions of both MMP-2 isoforms in
diabetic mouse heart compared to the control group (p<0.05) (by Aperio Image Scope v12.3.2.8013, Leica Biosystems Pathology Imaging, USG).
https://doi.org/10.1371/journal.pone.0221798.g004
Fig 5. High resolution analysis of MMP-2 isoform staining, and real-time quantitative PCR analysis. (A) Optical microscopic findings. The expression of the two
MMP-2 isoforms as determined by immunohistochemistry (IHC; Original magnification x200, x400). a, b: The expressions of both isoforms were minimal in control
mice. c, d: FL-MMP-2 staining showed FL-MMP-2 was mainly localized at sarcomeres, while NTT-MMP-2 staining shows NTT-MMP-2 was localized at Z- lines,
nuclei, and subsarcolemmal areas in diabetic mice (longitudinal section). e: Quantitative analysis of both isoforms staining shows significantly increased staining of both
MMP-2 isoforms in diabetic group compared to control group. (B) Real-time quantitative PCR of the two isoforms of MMP-2 in control and diabetic mouse hearts. FL-
and NTT-MMP-2 isoform transcripts were upregulated strongly in diabetic heart tissues. (C) High resolution (x1000) images showed that NTT-MMP-2 expressed the
specific area within cardiac muscle cells such as Z-line, intercalated disc and subsarcolemmal area where the mitochondria are abundant (red arrows). (D) In contrast
conversed image, these findings could be identified (blue lines) consistent with the previous results (18,19,22).
https://doi.org/10.1371/journal.pone.0221798.g005
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fold-increase in NTT-MMP-2 transcript was bigger but without statistical significance due to
low number of animals.
Fig 6. Enzymatic activities measured by zymography. (A) Gelatin zymography of the non-diabetic control and diabetic mouse hearts. Zones of
lysis denote gelatin enzymatic activity for MMP-2 (68kDa). (B) MMP-2 enzymatic activity was greater in diabetic heart tissues than in controls.
Band intensities were quantified by measuring pixel intensities. MMP-2 enzymatic activity was greater in diabetic heart tissues than in non-diabetic
control hearts (1.03±0.04 vs. 1.49±0.03, p = 0.029).
https://doi.org/10.1371/journal.pone.0221798.g006
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Fig 7. The relationship between NTT-MMP-2 expression and degree of mitochondrial damage. a~d: Electron microscopic analysis of control and diabetic heart
tissues. a: This image shows well-organized sarcomeres and mitochondria in control heart tissues (x12000). b: The image shows small, fragmented mitochondria among
sparse and widened sarcomeres in diabetic mouse heart (x10000). c: Image showing damaged, ruptured mitochondria with discharges (arrow) and fissuring of
mitochondria (arrowheads) at high resolution in a diabetic mouse heart (x25000). d: The degrees of mitochondrial damage (as assessed using our semi-quantitative
scoring system) were related to the NTT-MMP-2.
https://doi.org/10.1371/journal.pone.0221798.g007
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Discussion
The principal findings of this study are that the FL-MMP-2 and NTT-MMP-2 isoforms of
MMP-2 are induced by hyperglycemic stimuli in both in vitro and in vivo diabetic cardiac
models. This is the first report of the expression of the FL-MMP-2 and NTT-MMP-2 isoform
in a model of Type I diabetic cardiomyopathy. As was reported in a previous study of an I/R
cardiac injury model by Lovett, et al.[18], the two MMP-2 isoforms were associated with dis-
tinctive intracellular structures in cardiomyocytes. FL-MMP-2 was localized mainly to cardio-
myocyte sarcomeres, whereas NTT-MMP-2 was concentrated in the subsarcolemmal space,
where mitochondria are abundant. In addition, we observed NTT-MMP-2 immunohisto-
chemical staining within Z-lines, intercalated discs, and nuclei. These non-mitochondrial
localizations of the NTT-MMP isoform appear to be distinctive to the diabetic cardiomyopa-
thy model, as we previously found that cardiac specific transgenic expression of the
NTT-MMP-2 within normal mice resulted in only mitochondrial localization [18]. Mitochon-
drial morphological changes characteristic of the mitochondrial permeability transition were
observed in diabetic cardiomyocytes and the degrees of mitochondrial damage were found to
be positively correlated with the degree of NTT-MMP-2 expression as determined by
qRT-PCR.
The histological characteristics of human diabetic cardiomyopathy are only partially pres-
ent in the hearts examined in this study. The well-known histological characteristics of estab-
lished cardiomyopathy in the Type 1 diabetes mellitus are cardiomyocyte hypertrophy,
interstitial collagen deposition, and LV fibrosis [4,23]. In addition, in early diabetic cardiomy-
opathy there is mitochondrial dysfunction in terms of energy production, and increased oxida-
tive stress. Structurally there is decreased LV wall thickness, increased LV diameter and
volume, diminished LV ejection fraction and cardiac output. Further, an increased E/A ratio
are evident, which is consistent with combined systolic and diastolic dysfunction [24–26]. The
insulin resistance and hyperinsulinemia which occur in humans with prediabetic metabolic
syndrome are major pathophysiological factors in the type 2 diabetic cardiomyopathy [27].
These factors are responsible for the collagen deposition, LV fibrosis, and predominant dia-
stolic dysfunction observed in type 2 diabetic cardiomyopathy, whereas systolic dysfunction
without predominant fibrosis is observed in the type 1 diabetic heart [28]. The in vivo echocar-
diographic and histologic data obtained during this study showed significant systolic dysfunc-
tion and chamber dilation preceded fibrotic change, which was not observed until 24 weeks.
These results are in line with those of previous studies on type 1 DM, as described above. The
intracellular pathologies described in this report, particularly of the mitochondria may account
for the chamber dilation and cardiac systolic dysfunction prior to the development of apopto-
sis and fibrosis. Our results indicate the MMP-2, especially intracellularly located isoforms of
MMP-2, may be involved in the primarily functional changes seen in early type 1 diabetic
cardiomyopathy.
Experimental evidence shows that MMP-2 is activated in I/R injury and congestive heart
failure, and that pharmacological inhibitors of MMP activity or MMP-2 neutralizing antibody
prevent LV remodeling and aid recovery of mechanical function [29,30]. Moreover, myocar-
dial-specific overexpression of constitutively active FL-MMP-2 in mouse heart induced severe
LV remodeling, systolic dysfunction, sarcomere disruption, and mitochondrial damage even
in the absence of significant external injury [31,32]. In addition to the proteolytic removal of
pro-peptide domain MMP-2 in the peri-cellular environment [33], MMP-2 can also be acti-
vated intracellularly by S-glutathionylation or phosphorylation [34,35], or even by alternative
splicing of its 1st intron by oxidative stress [18]. The FL-MMP-2 isoform has been shown to
degrade Troponin I and led to impair cardiac contractile function in I/R Injury [15], and
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myosin light chain-1 and the cytoskeletal proteins desmin, spectrin, α-actinin, and titin have
been shown to co-localize with MMP-2 [36]. Our study showed that the intracellular
FL-MMP-2 isoform was localized to the sarcomeres, which suggests intracellular MMP-2 is
also induced in diabetic cardiomyopathy and that it caused cardiac contractile dysfunction
during early stage DM CMP without inducing ECM fibrosis or LV remodeling. We also found
that NTT-MMP-2 was also induced in vivo and in vitro model of diabetes. Considering that
our previous study [18] demonstrated NTT-MMP-2 was localized to the mitochondria, the
mitochondrial damage observed in the present study may have been induced by NTT-MMP-2
activation. This mitochondrial change might explain the functional changes in our early DM
CMP model. Future studies on the role of the intracellular MMP-2 isoforms may result in
improving our understanding diabetes-induced cardiac pathophysiologic derangement and
aid the identification of new therapeutic targets in oxidative stress-induced cardiac diseases,
including DM-CMP.
There are some limitations in the present study. Especially, diabetic murine model in this
study did not show the prominent pathological histologic changes compatible with cardiomy-
opathy, and further studies using other diabetic murine models are needed to understand and
uncover the role of MMP-2 in diabetic cardiomyopathy. In addition, because it is unclear
whether intracellular isoform of MMP-2 is the cause or the result of diabetic cardiomyopathy,
further direct or indirect suppression studies should be conducted.
In conclusion, two isoforms of MMP-2 were expressed strongly in diabetic cardiac cells and
tissue and those MMP-2 isoforms may be related to the functional changes in diabetes and
structural changes by extension in the more advanced diabetic models.
Supporting information
S1 Fig. Histologic change in diabetic mouse hearts at 24 weeks. a, b, c: H&E stained control
and DM mouse sections. d, e, f: MT stained control and DM mouse sections. g, h, i: PAS
stained control and DM mouse sections. j, k, l: TUNEL stained control and DM mouse sec-
tions. Compared to control and DM 12week groups, thickened cardiomyocytes with increased
collagen accumulation and apoptosis were noted in H&E, MT, and TUNEL stain, respectively
at DM 24 week group.
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